PBYI
Puma Biotechnology Inc

6,866
Mkt Cap
$343.67M
Volume
301,752.00
52W High
$7.29
52W Low
$2.58
PE Ratio
9.21
PBYI Fundamentals
Price
$6.82
Prev Close
$6.80
Open
$6.79
50D MA
$6.19
Beta
0.86
Avg. Volume
408,164.65
EPS (Annual)
$0.6166
P/B
2.98
Rev/Employee
$1.34M
$122.87
Loading...
Loading...
News
all
press releases
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +22.25% and +2.39%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI
Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 405.0% during the 3rd quarter, according to its most recent 13F filing...
MarketBeat·15d ago
News Placeholder
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free...
PR Newswire·25d ago
News Placeholder
Zacks Research Issues Pessimistic Forecast for PBYI Earnings
Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research decreased their Q1 2027 earnings estimates for Puma Biotechnology in a research report issued to clients...
MarketBeat·28d ago
News Placeholder
Ritholtz Wealth Management Raises Stake in Puma Biotechnology, Inc. $PBYI
Ritholtz Wealth Management lifted its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 139.0% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·29d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above 200 Day Moving Average - What's Next?
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average - Here's What Happened
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average - Time to Sell...
MarketBeat·2mo ago
News Placeholder
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday...
Business Wire·2mo ago
News Placeholder
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Zacks·2mo ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.